Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Blood

Volumn 126, Issue 8, 2015, Pages 1005-1008

  Dietrich, Sascha ^a   Hüllein, Jennifer ^a   Lee, Stanley Chun Wei ^b   Hutter, Barbara ^a   Gonzalez, David ^c   Jayne, Sandrine ^d   Dyer, Martin J S ^d   Oleś, Małgorzata ^a   Else, Monica ^e   Liu, Xiyang ^a   Słabicki, Mikołaj ^a   Wu, Bian ^a   Troussard, Xavier ^f   Dürig, Jan ^g   Andrulis, Mindaugas ^h   Dearden, Claire ⁱ   Von Kalle, Christof ^a   Granzow, Martin ^j   Jauch, Anna ^j   Fröhling, Stefan ^a   Huber, Wolfgang ^a   Meggendorfer, Manja ^k   Haferlach, Torsten ^k   Ho, Anthony D ^a   Richter, Daniela ^a   Brors, Benedikt ^a   Glimm, Hanno ^a   Matutes, Estella ⁱ   Wahab, Omar Abdel ^b   Zenz, Thorsten ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f CHU CÔTE DE NACRE   (France)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k MLL MUNICH LEUKEMIA LABORATORY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; HISTONE DEMETHYLASE; HISTONE H3; PURINE DERIVATIVE; RETINOBLASTOMA BINDING PROTEIN 2; TRANSCRIPTION FACTOR EZH2; VEMURAFENIB; CDKN1B PROTEIN, HUMAN;

ARTICLE; CELL CYCLE REGULATION; COPY NUMBER VARIATION; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; SENESCENCE; SEQUENCE ANALYSIS; WHOLE EXOME SEQUENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NUCLEOTIDE SEQUENCE;

CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, HAIRY CELL; MUTATION; RECURRENCE;

EID: 84940042389     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-643361     Document Type: Article

References (19)

1. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-28.
2. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
3. Chung SS, Kim E, Park JH, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014;6(238):238ra271.
4. Jethwa A, Hüllein J, Stolz T, et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol. 2013;163(4):496-500.
5. Yaktapour N, Meiss F, Mastroianni J, et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014;124(11):5074-5084.
6. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
7. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8-10.
8. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370(3):286-288.
9. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322.
11. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038-2040.
12. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253-267.
13. Milne TA, Hughes CM, Lloyd R, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA. 2005;102(3):749-754.
14. Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483-1486.
15. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
16. Le Toriellec E, Despouy G, Pierron G, et al. Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. Blood. 2008;111(4):2321-2328.
17. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720-724.
18. Dietrich S, Hüllein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013;31(19):e300-e303.
19. Motti ML, De Marco C, Califano D, et al. Loss of p27 expression through RAS - > BRAF - > MAP kinase-dependent pathway in human thyroid carcinomas. Cell Cycle. 2007;6(22):2817-2825.